Natera (NTRA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.47
- Estimate
- -$0.53
- Surprise
- +12.0%
- Revenue (period 2026-06-30)
- $752.8M
- Score at report (before → after)
- 5.8 → 5.9/10
Revenue source: xbrl.
How the report landed
Natera (NTRA) reported a narrower loss than forecast — adjusted EPS of -$0.47 against the -$0.53 estimate (a 12.0% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Hold (5.8/10) to Sell at 5.9/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates NTRA Sell at 5.1/10.
2 of the last 4 quarters beat the estimate; this quarter's +12.0% surprise compares with a +22.6% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- Analyst target reached - limited upside remaining
- Near 52-week high (3.0% away)
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $424.35
- Stop
- $394.64
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
NTRA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $61.18B
- P/E (fwd)
- -2386.5
- 52-week range
- $181.00–$437.41
- Off 52-week high
- 3.0%
- RSI (14)
- 64
- Volume vs avg
- 0.03×
- Score today
- 5.1/10